Cargando…

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort

INTRODUCTION: Little information is available on the efficacy and safety of the dual combination of ripivirine plus dolutegravir. This work aims at beginning to fill this gap. METHODS: All HIV-1 infected subjects treated with ripivirine plus dolutegravir between October 2014 and September 2015 in ei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Capetti, Amedeo F., Sterrantino, Gaetana, Cossu, Maria Vittoria, Orofino, GianCarlo, Barbarini, Giorgio, De Socio, Giuseppe V., Di Giambenedetto, Simona, Di Biagio, Antonio, Celesia, Benedetto M., Argenteri, Barbara, Rizzardini, Giuliano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065232/ https://www.ncbi.nlm.nih.gov/pubmed/27741309 http://dx.doi.org/10.1371/journal.pone.0164753

Ejemplares similares

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

Is Dolutegravir Plus Atazanavir Overburdened With Concentration-Related Neurological Events Compared With Other Dual Regimens?
por: Capetti, Amedeo F, et al.
Publicado: (2019)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019)

Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV
por: Guaraldi, Giovanni, et al.
Publicado: (2021)

Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens
por: Maggi, Paolo, et al.
Publicado: (2023)

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients
por: Fabbiani, Massimiliano, et al.
Publicado: (2023)

Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort
por: Ciccullo, Arturo, et al.
Publicado: (2022)

96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience
por: Capetti, Amedeo, et al.
Publicado: (2012)

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project
por: Bagella, Paola, et al.
Publicado: (2018)

Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems
por: Melzi, Sara, et al.
Publicado: (2010)

Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study
por: Palacios, Rosario, et al.
Publicado: (2018)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers, Ellen, et al.
Publicado: (2018)

Shall We Dance? Extending TANGO’s Results to Clinical Practice
por: Borghetti, Alberto, et al.
Publicado: (2020)

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
por: Maggi, Paolo, et al.
Publicado: (2023)

Factors Associated With Weight Gain in People Treated With Dolutegravir
por: Taramasso, Lucia, et al.
Publicado: (2020)

Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort
por: Bonfanti, Paolo, et al.
Publicado: (2020)

Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers
por: Capetti, Amedeo F., et al.
Publicado: (2020)

Trajectories of CD4(+)/CD8(+) T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study
por: Taramasso, Lucia, et al.
Publicado: (2022)

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
por: Bagella, Paola, et al.
Publicado: (2019)

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients
por: Riccardi, Niccolò, et al.
Publicado: (2019)

2541. Steady-state PK of Fixed Dose Dolutegravir+Rilpivirine in Hemodialysis
por: Gupta, Samir K, et al.
Publicado: (2023)

Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience
por: Landonio, S, et al.
Publicado: (2010)

2485. Real-world Experience with Dolutegravir Plus Rilpivirine Two-Drug Regimen
por: Ward, Douglas, et al.
Publicado: (2019)

Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
por: Troya, Jesús, et al.
Publicado: (2022)

Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2022)

Decay rate of antiS1/S2 IgG serum levels after 6 months of BNT162b2 vaccination in a cohort of COVID-19-naive and COVID-19-experienced subjects
por: Borgonovo, Fabio, et al.
Publicado: (2022)

Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era
por: Sterrantino, Gaetana, et al.
Publicado: (2012)

Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health
por: McComsey, Grace A., et al.
Publicado: (2018)

The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet
por: Mehta, Rashmi, et al.
Publicado: (2020)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)
por: Taramasso, Lucia, et al.
Publicado: (2018)

Persistence of Long-COVID symptoms in a heterogenous prospective cohort
por: Mariani, Chiara, et al.
Publicado: (2022)

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection
por: Mehta, Rashmi, et al.
Publicado: (2018)

Efficacy of switching to dolutegravir plus rilpivirine, the small-tablet regimen, in patients with dysphagia: two case reports
por: Suzuki, Takefumi, et al.
Publicado: (2017)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
por: Restelli, Umberto, et al.
Publicado: (2017)

Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2
por: Llibre, Josep M., et al.
Publicado: (2022)

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023)

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia
por: Taramasso, Lucia, et al.
Publicado: (2019)

One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG
por: Capetti, Amedeo F., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_drolv4ak2jbo8mrjjouaiq89nd